



April 30, 2025

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001  
Scrip code: 532531

**The National Stock Exchange of India Limited**

Exchange Plaza, Bandra-Kurla Complex  
Bandra (E) Mumbai - 400 051  
Scrip code: STAR

Dear Madam/ Sir,

**Sub: Press Release**

Please find attached Press Release issued by the Company titled:

**“Strides Strengthens Anti-Inflammatory Portfolio with USFDA Approval for  
Celecoxib Capsules, 100 mg, 200 mg, and 400 mg”**

Thanks & Regards,  
For **Strides Pharma Science Limited**,

**Manjula Ramamurthy**  
**Company Secretary**  
**ICSI Membership No. A30515**

Encl. As above

**Strides Pharma Science Limited**

CIN: L24230MH1990PLC057062

**Corp. Off:** Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India

**Tel:** +91-80-6784 0000 **Fax:** +91 80 6784 0700

**Regd Off:** 'Cyber One', Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703, India

**Tel:**+91-22-2789 2924/ 3199

corpcomm@strides.com; www.strides.com

## Strides Strengthens Anti-Inflammatory Portfolio with USFDA Approval for Celecoxib Capsules, 100 mg, 200 mg, and 400 mg

- *Celecoxib Capsules approval complements Strides' existing products to serve a broader patient base*

**Bangalore, India, April 30, 2025** - Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Celecoxib Capsules, 100 mg, 200 mg, and 400 mg, from the United States Food & Drug Administration (USFDA).

The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Celebrex® Capsules, 100 mg, 200 mg, and 400 mg, of Upjohn US 2 LLC.

The approval of Celecoxib Capsules strengthens Strides' portfolio in the anti-inflammatory therapeutic segment. This approval complements the company's existing products in the same therapy area and enhances its ability to serve a broader patient population with effective, affordable treatment options. Celecoxib is a selective COX-2 inhibitor used for the management of pain and inflammation associated with various conditions including osteoarthritis, rheumatoid arthritis, acute pain, and dysmenorrhea. Celecoxib Capsules, 100 mg, 200 mg, and 400 mg have a combined market size of ~US\$ 116 Mn as per IMS.

The product will be manufactured at the company's facility in Puducherry.

### About Celecoxib Capsules

Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that works by reducing hormones that cause inflammation and pain in the body. It is commonly prescribed to manage symptoms of arthritis, pain, and other inflammatory conditions.

### About Strides

Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy and an institutional business to service donor-funded markets. The Company's global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on "difficult to manufacture" products sold in over 100 countries. Additional information is available at the Company's website at [www.strides.com](http://www.strides.com).

For further information, please contact:

**Institutional Investors**

**Vikesh Kumar**

Group CFO

[investor-relations@strides.com](mailto:investor-relations@strides.com)

**Saurabh Ambaselkar**

Investor Relations

+91 99609 31220

[saurabh.ambaselkar@strides.com](mailto:saurabh.ambaselkar@strides.com)

**Strides Pharma Science Limited**

CIN: L24230MH1990PLC057062

Corp. Office: Strides House, Bannerghatta Road,  
Bengaluru – 560076

**Corporate Communication**

**Pallavi Panchmatia:** +91 80 6784 0193

[Pallavi.panchmatia@strides.com](mailto:Pallavi.panchmatia@strides.com)

**PR Consultancy**

Adfactors PR

**Janhavi Bellare:** +91 93228 54508

[Janhavi.bellare@adfactorspr.com](mailto:Janhavi.bellare@adfactorspr.com)

**Talal Syed:** +91 99876 19679

[syed.talal@adfactorspr.com](mailto:syed.talal@adfactorspr.com)